Amrita Krishnan

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Cyrille Touzeau, Amrita Krishnan, Philippe Moreau et al. · Blood · 2024 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Joshua Richter, Sheeba K. Thomas, Amrita Krishnan et al. · Blood · 2024 · 29 citations · Full text

Medicine, Oncology, Pharmacology +13

Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

Marcelo C. Pasquini, Paul K. Wallace, Brent R. Logan et al. · Journal of Clinical Oncology · 2024 · 19 citations · Full text

Medicine, Hematology, Oncology +17

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Mariam Murtadha, Miso Park, Yinghui Zhu et al. · Blood · 2024 · 13 citations · Full text

Life Sciences, Immunology, Oncology +11